Plain-English translation of NCT05906056 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
After a serious brain injury, stroke, or spinal cord injury, some patients develop unwanted bone growth in their joints—a condition called heterotopic ossification. This trial is testing whether a painless treatment called continuous passive motion (CPM), which gently and continuously stretches the affected joint, can prevent this bone growth from forming. All participants will also receive a single dose of zoledronic acid (Aclasta), a medication that may help reduce bone formation.
Abnormal bone growth in joints can cause pain, stiffness, and loss of movement in patients recovering from serious neurological injuries. Doctors want to know if combining gentle, continuous stretching with the medication can better protect patients from this complication than standard physical therapy alone.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be assigned to one of two groups. One group will receive continuous passive motion therapy—a machine that gently and slowly stretches your affected joint for extended periods while you rest—along with standard physical therapy and the medication. The other group will receive standard physical therapy and the medication without the stretching machine. Researchers will take imaging tests (CT scans) and measure your joint movement at the beginning and end of the study to see which approach works better at preventing bone growth.
AI-generated summary from trial data · Jul 13, 2026 · Not medical advice
Greece